Kugelmeiers contributes to and provides accessibility to regenerative medicine, believing it to be a potential for future medical therapies that everyone should have the opportunity to commit towards. We developed as a result of 18 years of research and dedication in the field of transplant surgery,  cell therapy and developmental biology a technology allowing us to make an impact on islet, liver and many other cell therapies that rely on 3D spheroids that need a medical quality platform.

Our first product, the Sphericalplate 5D, is a platform enabling advanced 3D culturing, as well as safe clinical use of stem cells. Cell culture geometry and surface are decisive for communication in between stem cells and their early differentiation. This is a prerequisite for safe regenerative medicine applications. During their development stem cells need physiological enviroment in order to reduce the risk of uncontrolled differentiation. 

We are embarking on an exciting growth phase in the field of advanced cell therapies. The global cell culture research market is changing form 2D to 3D. The Sphericalplate 5D is the solution covering the entire application range with unrivaled user advantages.

Our company was founded in 2015 as a spin-off from the University of Zurich in Switzerland. We are a team of 22 specialists who develop and market cutting-edge 3D cell culture technologies. In 2020, we plan to begin the first human trial, together with four leading European transplant centres.